FIA
MLYS icon

FNY Investment Advisers’s Mineralys Therapeutics MLYS Stock Holding History

FNY Investment Advisers’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67K Buy
2,500
+2,000
+400% +$54.9K 0.02% 374
2026
Q1 		$13K Buy
+500
New +$14.7K 0.01% 521
2025
Q3 		– Sell
-1,500
Closed -$20K – 1413
2025
Q2 		$20K Hold
1,500
– – 0.01% 555
2025
Q1 		$23K Buy
+1,500
New +$17.3K 0.01% 379

Other funds holding MLYS

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

FNY Investment Advisers's MLYS Position: Q2 2026 in Review

FNY Investment Advisers increased its Mineralys Therapeutics (MLYS) stake by 400% in Q2 2026, buying an estimated $54.9K and bringing the position to 2,500 shares worth $67K. The position accounts for 0.02% of the portfolio, ranked #374.

FNY Investment Advisers first reported a position in MLYS in Q1 2025 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • FNY Investment Advisers held 2,500 shares of Mineralys Therapeutics worth $67K as of Q2 2026.
  • FNY Investment Advisers bought 2,000 Mineralys Therapeutics shares in Q2 2026, an estimated $54.9K.
  • Mineralys Therapeutics made up 0.02% of FNY Investment Advisers's portfolio in Q2 2026, its #374 holding.
  • FNY Investment Advisers first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 9 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.